Trial · NCT04743908
Community Network-driven COVID-19 Testing and Vaccination of Vulnerable Populations in the Central US
NCT04743908, Not applicable, Completed, University of Chicago; results first posted 2024-10-10
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Community Network-driven COVID-19 Testing and Vaccination of Vulnerable Populations in the Central US. Trials, record NCT04743908. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04743908
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Community Network-driven COVID-19 Testing and Vaccination of Vulnerable Populations in the Central US
- NCT number
- NCT04743908
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 1,328 participants, actual
- Lead sponsor
- University of Chicago
- Conditions
- Covid19
- Interventions
- Social Network Strategy + COVID-19 messaging
- First posted
- 2021-02-08
- Last updated
- 2024-10-10
- Results first posted
- 2024-10-10
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Total Number of Tests Among Network Members Referred for COVID Testing (Network Tested). | 21 days from initial study visit for each participant | Network tested is measured at the participant level by the number of network members that are tested through the SNS. |
| Primary | Total Number of Vaccinations Among Study Participants Given COVID Vaccine Information (Number Vaccinated) | 21 days from initial study visit for each participant | Number vaccinated is measured at the participant level by the number of study participants that are vaccinated through the SNS. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Total Number of Tests Among Network Members Referred for COVID Testing (Network Tested). | 21 days from initial study visit for each participant | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Total Number of Vaccinations Among Study Participants Given COVID Vaccine Information (Number Vaccinated) | 21 days from initial study visit for each participant | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Total Number of Tests Among Network Members Referred for COVID Testing (Network Tested). | Social Network Strategy (SNS Condition) | Tested | 444 | Participants | |
| Total Number of Tests Among Network Members Referred for COVID Testing (Network Tested). | Social Network Strategy + Messaging | Tested | 437 | Participants | |
| Total Number of Tests Among Network Members Referred for COVID Testing (Network Tested). | Social Network Strategy (SNS Condition) | Not Tested | 196 | Participants | |
| Total Number of Tests Among Network Members Referred for COVID Testing (Network Tested). | Social Network Strategy + Messaging | Not Tested | 206 | Participants | |
| Total Number of Tests Among Network Members Referred for COVID Testing (Network Tested). | Social Network Strategy (SNS Condition) | Missing Testing Data | 21 | Participants | |
| Total Number of Tests Among Network Members Referred for COVID Testing (Network Tested). | Social Network Strategy + Messaging | Missing Testing Data | 24 | Participants | |
| Total Number of Vaccinations Among Study Participants Given COVID Vaccine Information (Number Vaccinated) | Social Network Strategy (SNS Condition) | Vaccinated | 18 | Participants | |
| Total Number of Vaccinations Among Study Participants Given COVID Vaccine Information (Number Vaccinated) | Social Network Strategy + Messaging | Vaccinated | 27 | Participants | |
| Total Number of Vaccinations Among Study Participants Given COVID Vaccine Information (Number Vaccinated) | Social Network Strategy (SNS Condition) | Not Vaccinated | 81 | Participants | |
| Total Number of Vaccinations Among Study Participants Given COVID Vaccine Information (Number Vaccinated) | Social Network Strategy + Messaging | Not Vaccinated | 94 | Participants |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Social Network Strategy (SNS Condition) | 661 | |
| Overall Study | STARTED | Social Network Strategy + Messaging | 667 | |
| Overall Study | COMPLETED | Social Network Strategy (SNS Condition) | 478 | |
| Overall Study | COMPLETED | Social Network Strategy + Messaging | 485 | |
| Overall Study | NOT COMPLETED | Social Network Strategy (SNS Condition) | 183 | |
| Overall Study | NOT COMPLETED | Social Network Strategy + Messaging | 182 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Hospitalization | Respiratory, thoracic and mediastinal disorders | Social Network Strategy (SNS Condition) | 1 | 661 | |
| serious | Hospitalization | Respiratory, thoracic and mediastinal disorders | Social Network Strategy + Messaging | 0 | 667 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Social Network Strategy (SNS Condition) | 1 | 661 |
| Total, all-cause mortality | Social Network Strategy + Messaging | 2 | 667 |
| Total, other adverse events | Social Network Strategy (SNS Condition) | 0 | 661 |
| Total, other adverse events | Social Network Strategy + Messaging | 0 | 667 |
| Total, serious adverse events | Social Network Strategy (SNS Condition) | 1 | 661 |
| Total, serious adverse events | Social Network Strategy + Messaging | 0 | 667 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| UG1DA050066 | Reducing Opioid Mortality in Illinois (ROMI) | POLLACK, HAROLD ALEXANDER; PHO, MAI TUYET; SCHNEIDER, JOHN | UNIVERSITY OF CHICAGO | NATIONAL INSTITUTE ON DRUG ABUSE | 2019 to 2023 |
Source NIH RePORTER
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Social Network Strategy (SNS Condition) vs Social Network Strategy + Messaging: deaths from any cause | Trial comparisons |
| Social Network Strategy (SNS Condition) vs Social Network Strategy + Messaging: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04743908
GET https://conductscience.org/api/trials/v1/NCT04743908/registered